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INTRODUCTION {#psyg12440-sec-0005}
============

Mild cognitive impairment (MCI) is a transitional phase between healthy cognitive aging and Alzheimer\'s disease (AD).[1](#psyg12440-bib-0001){ref-type="ref"} MCI is more likely to develop into AD than in the normal population.[2](#psyg12440-bib-0002){ref-type="ref"} The MCI population develops dementia at a rate of 10--15% per year, while the overall population develops 1--2% of dementia per year.[3](#psyg12440-bib-0003){ref-type="ref"} About 60% of MCI people develop AD within 10 years.[4](#psyg12440-bib-0004){ref-type="ref"} However, no effective treatment for dementia has been found. Therefore, how to diagnose and provide early intervention with MCI is receiving more and more attention.

In recent years, with the in‐depth study of the pathogenesis of MCI, genetic factors have received extensive attention in the aetiology of MCI. Identification of a MCI‐causing gene will undoubtedly bring new ways to prevent and treat this cognitive disorder. Recent studies have found that genetic polymorphisms are associated with MCI,[5](#psyg12440-bib-0005){ref-type="ref"}, [6](#psyg12440-bib-0006){ref-type="ref"}, [7](#psyg12440-bib-0007){ref-type="ref"}, [8](#psyg12440-bib-0008){ref-type="ref"} while many previous studies have shown that bridging integrator 1 (*BIN1*), sortilin‐related receptor 1 (*SORL1*), presenilin 2 (*PSEN2*) and nerve growth factor (*NGF*) and 8‐oxoguanine DNA glycosylase 1 (*OGG1*) gene polymorphisms and protein phenotypes are associated with cognitive decline and nervous system degenerative disease. *BIN1* affects cognitive function by regulating tau protein,[9](#psyg12440-bib-0009){ref-type="ref"} which regulates the transport and recycling of amyloid‐β (Aβ) protein precursor protein in the pathogenesis of AD and MCI,[10](#psyg12440-bib-0010){ref-type="ref"} and its polymorphism is associated with decreased Aβ concentration in cerebrospinal fluid.[11](#psyg12440-bib-0011){ref-type="ref"}, [12](#psyg12440-bib-0012){ref-type="ref"}, [13](#psyg12440-bib-0013){ref-type="ref"} Mutations in the *PSEN2* gene have been identified in association with early‐onset AD (EOAD), and recent studies have found that it can also lead to Ca^2+^ homeostasis, which in turn induces neurodegenerative diseases.[14](#psyg12440-bib-0014){ref-type="ref"} NGF plays an important role in the pathogenesis of AD.[15](#psyg12440-bib-0015){ref-type="ref"} In recent years, studies have found that treatment of AD with NGF can improve cognitive function and decrease the level of Aβ protein in cerebrospinal fluid.[16](#psyg12440-bib-0016){ref-type="ref"} OGG1 can degrade 8‐oxoG, reduce its damage on DNA, and thus reduce the damage of oxidative stress on brain cells.[17](#psyg12440-bib-0017){ref-type="ref"} OGG1 begins to decline in activity at the MCI stage, which promotes the progression of MCI to AD.[18](#psyg12440-bib-0018){ref-type="ref"} However, there are relatively few studies on whether the above gene polymorphisms are associated with MCI.

Epigenetics can modify aging and environmental factors.[19](#psyg12440-bib-0019){ref-type="ref"} DNA methylation is a major component of epigenetics involved in the pathophysiological processes of neurodegenerative diseases such as AD, other types of dementia, and cognitive decline.[20](#psyg12440-bib-0020){ref-type="ref"} Due to its relative stability and its ability to be directly regulated by underlying genetic sequences and environmental exposure, DNA methylation is thought to be a biomarker for brain‐related diseases or disorders.[21](#psyg12440-bib-0021){ref-type="ref"} MCI is a precursor stage of AD, and cognitive function has been damaged to varying degrees. Its pathogenesis is affected by genetics and environment.[22](#psyg12440-bib-0022){ref-type="ref"} DNA methylation may play an important role in the development of MCI.[23](#psyg12440-bib-0023){ref-type="ref"} Our previous studies also found that DNA methylation of genes were associated with MCI.[24](#psyg12440-bib-0024){ref-type="ref"}, [25](#psyg12440-bib-0025){ref-type="ref"}

The ancestors of the Xinjiang Uygur population are Hui, and their bloodlines are mixed with Mongolian races and European races.[26](#psyg12440-bib-0026){ref-type="ref"} Therefore, the Chinese Uyghur bloodline composition is diversified, and there is a large genetic difference with the Chinese Han population. Moreover, the geographical environment, life and eating habits of Xinjiang in China are quite different from those in the inland areas of China, which may have an impact on the occurrence and development of diseases. Therefore, it is necessary to conduct genetic research in the Chinese Uyghur population.

Therefore, in order to further explore the relationship between the above genetic polymorphisms and MCI, this study examined the relationship of five gene polymorphisms (*OGG1* rs1052133, *BIN1* rs744373, *SORL1* rs1133174, *PSEN2* rs8383 and *NGF* rs6330) and promoter methylation of *OGG1* and dihydrolipoamide S‐succinyltransferase (*DLST*) with MCI in a Xinjiang Uygur population. Our study provides a valuable evaluation of the role of these AD‐related genes in MCI in this unique ethnic population.

MATERIALS AND METHODS {#psyg12440-sec-0006}
=====================

Samples and clinical data {#psyg12440-sec-0007}
-------------------------

One hundred and sixty‐eight Uygur participants aged between 50 and 95 years (43 MCI, 125 cognitively normal) were selected at epidemiological surveys in 2015 in Hotan, Xinjiang. The patients' detailed characteristics are shown in Table [1](#psyg12440-tbl-0001){ref-type="table"}. The epidemiology and related investigation were approved by the First Affiliated Hospital of Xinjiang Medical University Ethics Committee. All participants have provided their written informed consent.

###### 

The baseline clinical data of the included subjects

  Characteristics   MCI *N* = 43     Control *N* = 125   Test value   *P*
  ----------------- ---------------- ------------------- ------------ -------
  Age (year)        71.56 ± 9.32     71.77 ± 8.16        t = −0.14    0.889
  SBP (mmHg)        147.65 ± 29.20   140.52 ± 25.79      t = 1.51     0.133
  DBP (mmHg)        79.93 ± 15.50    76.11 ± 15.91       Z = −1.46    0.143
  TC (mmol/L)       4.98 ± 1.02      4.80 ± 1.21         t = 0.87     0.383
  TG (mmol/L)       1.69 ± 1.01      1.83 ± 1.19         Z = −0.83    0.406
  HDL (mmol/L)      1.50 ± 0.32      1.49 ± 0.59         Z = −0.69    0.493
  LDL (mmol/L)      3.46 ± 0.88      3.14 ± 1.01         t = 1.90     0.059
  GLU (mmol/L)      4.77 ± 1.44      4.63 ± 1.10         Z = −0.13    0.897

  Gender                      *n* (%)        *n* (%)                      
  --------------------------- -------------- ------------- -------------- -------
  Male                        22 (51.2%)     65 (52.0%)     χ^2^ = 0.009   0.924
  Female                      21 (48.8%)     60 (48.0%)                   
  Diabetes                                                                
  Yes                         1 (2.3%)       1 (0.8%)           ---        0.448
  No                          42 (97.7%)     124 (99.2%)                  
  Hypertension                                                            
  Yes                         20 (46.5%)     51 (40.8%)     χ^2^ = 0.428   0.513
  No                          23 (53.5%)     74 (59.2%)                   
  Cerebral vascular disease                                               
  Yes                         5 (11.6%)      9 (7.2%)           ---        0.353
  No                          38 (88.4%)     116 (92.8%)                  
  Smoke                                                                   
  No                          38 (88.4%)     110 (88%)      χ^2^ = 0.004   0.948
  Yes                         5 (11.6%)      15 (12%)                     
  Drink                                                                   
  No                          43 (100%%)     0 (0.0%)           ---          1
  Yes                         124 (99.2%)    1 (0.8%)                     
  *APOE* ε4 carrier           7 (18.4%)      31 (81.6%)     χ^2^ = 1.050   0.306
  *APOE* non‐ε4 carrier       33 (26.6.4%)   91 (73.4%)                   

MCI, mild, cognitive impairment; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglycerides; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; GLU, glucose; *APOE*, apolipoprotein E

All participants received neuropsychological tests to assess the level of cognition. Neuropsychological tests included: the Mini‐Mental State Examination (MMSE), the Montreal Cognitive Assessment Form (MoCA), Activities of Daily Living (ADLs) Scale, the overall Deterioration Scale (GDS), the Clinical Dementia Rating (CDR), and Hachinski ischaemic score (HIS) screening. Diagnosis criteria: a clinical diagnosis of AD was established according to the criteria of the Diagnostic and Statistical Manual‐IV (DSM‐IV).[27](#psyg12440-bib-0027){ref-type="ref"} Exclusion criteria for the current study were: (i) those with mental illness; (ii) any brain dysfunction that can cause neurological diseases such as cerebral haemorrhage, cerebral infarction, Parkinson\'s disease (PD), intracranial tumours; (iii) depression; and (iv) patients with severe cardiopulmonary liver and kidney dysfunction, severe infectious diseases, severe endocrine disease patients and toxic encephalopathy patients.

The blood biochemical indicators (including total cholesterol (TC), triglycerides (TG), high‐density lipoprotein (HDL), low‐density lipoprotein (LDL), glucose (GLU)) were detected by an automatic biochemical analyzer (Beckman Coulter, Brea, CA, USA) at the Medical Testing Center of the First Affiliated Hospital of Xinjiang Medical University. Blood pressure (including systolic blood pressure (SBP), diastolic blood pressure (DBP)) was measured using a uniform sphygmomanometer (Omron Corporation, Kyoto, Japan).

DNA preparation, genotyping and methylation assay {#psyg12440-sec-0008}
-------------------------------------------------

Whole blood specimens were placed in tubes containing EDTA and stored at −80°C. Genomic DNA was extracted and dissolved in Tris‐EDTA buffer, and then it was stored at −20°C. Polymerase chain reaction (PCR) was carried out in 40 μL containing 2 μL of each primer, 4 μL genomic DNA, 12 μL ddH~2~O and 20 μL 2X HotTaq Master Mix. PCR was performed in a Veriti 96‐well thermal cycler (Applied Biosystems, Foster City, CA, USA).The reverse primers of PCR consisted of an initial melting step at 95°C for 10 min, 35 cycles (*NGF*, *BIN1*, and *OGG1*) or 37 cycles (*PSEN2*) or 40 cycles (*SORL1*), and a final extension step at 72°C for 2 min. The cycling program was 95°C for 30 s, 58°C (*NGF* and *BIN1*) or 54°C (*OGG1*) or 57°C (*PSEN2*) or 53°C (*SORL1*) for 45 s for annealing, and 72°C for 30 s. The details for the primer sequences were shown in Table [2](#psyg12440-tbl-0002){ref-type="table"}. Genotyping was done using Sanger sequencing, gel electrophoresis and sequencing validation as shown in Figure [1](#psyg12440-fig-0001){ref-type="fig"}. DNA bisulphite conversion was done using the EZ DNA Methylation‐Gold™ Kit (ZYMO RESEARCH, Orange County, CA, USA). Promoter methylation status of *OGG1* and *DLST* were examined utilizing quantitative methylation‐specific PCR (qMSP). Primer sequences of *OGG1* and *DLST* qMSP are shown in Table [3](#psyg12440-tbl-0003){ref-type="table"}.

###### 

Primers used for single nucleotide polymorphism analysis

  Gene                   Forward primer (5′--3′)   Reverse primer (5′--3′)   °C
  ---------------------- ------------------------- ------------------------- ------
  *PSEN2* (rs8383)       TTACTTCTCCACGGACAAC       CAAGATTCTAACAGGACTCATC    55.3
  *BIN1* (rs744373)      GCCAGTCCATCTTCTTCT        ACCACATCTTAGCCACAG        57.6
  *NGF* (rs6330)         CATCCATACTGCCTGAGTC       CCTGTGAGTCCTGTTGAAG       57.3
  *OGG1* (rs1052133)     GTGGATTCTCATTGCCTTC       AAACTGACTGCTTGATTTGG      57.5
  *SORL1* (rs1133174)    TGTGACTTGTGCTGTATGAT      ACGCTAGAAGAAGGCTTATC      51.5
  *OGG1* (methylation)   CGGTGGTTGAGTTTTATTTTC     CTCCTTACGACTTATCTTCTC     56.1
  *DLST* (methylation)   GTTGTAGTCGGGATATTGG       CGAAACGAACCACTAACA        53.3

![Representative results of gel electrophoresis and sequencing validation.](PSYG-19-574-g001){#psyg12440-fig-0001}

###### 

Distribution frequencies of genotypes in mild cognitive impairment (MCI) cases and controls

  Single nucleotide polymorphisms    MCI; Control (MM/Mm/mm)  *P* Genotype    MCI; Control (M/m)  *P* Allele   OR (95%CI)
  --------------------------------- ------------------------- -------------- -------------------- ------------ ----------------------
  Total                                                                                                        
  *BIN1* rs744373 (T \> C)              20/22/1; 70/47/8      0.266             62/24; 187/63     0.621        0.870 (0.502--1.510)
  *NGF* rs6330 (C \> T)                 22/20/1; 65/55/5      0.950             64/22; 185/65     0.939        1.022 (0.583--1.791)
  *OGG1* rs1052133 (C \> G)            13/19/11; 40/62/23     0.594             45/41; 142/108    0.471        0.835 (0.511--1.365)
  *PSEN2* rs8383 (C \> T)               17/19/7; 43/56/26     0.751             53/33; 142/108    0.434        1.222 (0.740--2.017)
  *SORL1* rs1133174 (A \> G)            16/22/5; 50/63/12     0.872             54/32; 163/87     0.687        0.901 (0.541--1.498)
  Males                                                                                                        
  *BIN1* rs744373 (T \> C)              11/10/1; 35/26/4      0.919              32/12; 96/34     0.884        0.944 (0.437--2.040)
  *NGF* rs6330 (C \> T)                 12/10/0; 34/29/2      1.000              34/10; 97/33     0.724        1.157 (0.516--2.595)
  *OGG1* rs1052133 (C \> G)              8/8/6; 25/29/11      0.553              24/20; 79/51     0.468        0.775 (0.389--1.544)
  *PSEN2* rs8383 (C \> T)                8/9/5; 21/30/14      0.908              25/19; 72/58     0.869        1.060 (0.532--2.112)
  *SORL1* rs1133174 (A \> G)             6/13/3; 25/32/8      0.635              25/19; 82/48     0.461        0.770 (0.384--1.543)
  Females                                                                                                      
  *BIN1* rs744373 (T \> C)               9/12/0; 35/21/4      0.180              30/12; 91/29     0.572        0.797 (0.362--1.754)
  *NGF* rs6330 (C \> T)                 10/10/1; 31/26/3      0.913              30/12; 88/32     0.811        0.909 (0.416--1.988)
  *OGG1* rs1052133 (C \> G)             5/11/5; 15/33/12      0.934              21/21; 63/57     0.780        0.905 (0.448--1.827)
  *PSEN2* rs8383 (C \> T)               9/10/2; 22/26/12      0.547              28/14; 70/50     0.342        1.429 (0.684--2.985)
  *SORL1* rs1133174 (A \> G)             10/9/2; 25/31/4      0.676              29/13; 81/39     0.853        1.074 (0.504--2.291)

Statistical analysis {#psyg12440-sec-0009}
--------------------

SPSS 17.0 (SPSS Inc., Chicago, IL, USA) software was used for the statistical analysis. Comparison of demographical parameters between cases and controls was performed using Student\'s *t*‐test for continuous variables and the χ^2^ test for categorical data. Spearman rank correlation test was used to analyze the associations between gene methylation and metabolic characteristics of MCI subjects. The generalized multi‐factor dimensionality reduction (GMDR) method was used to study the effects of gene‐gene interactions and gene‐environment interactions on the pathogenesis of MCI. GMDR detects and characterizes the nonlinear interactions between genetic and environmental factors. *P* \< 0.05 was considered statistically significant.

RESULTS {#psyg12440-sec-0010}
=======

General comparisons of the MCI group and control group in this study involved gender, age, hypertension, diabetes, blood lipids (TG, TC, HDL, LDL), smoking and drinking status (Table [1](#psyg12440-tbl-0001){ref-type="table"}). Our results indicated there was no significant difference in the above phenotypes between the two groups (*P* \> 0.05).

In this study, the genotype and allele frequencies of the five single nucleotide polymorphisms (SNPs) were consistent with the Hardy‐Weinberg test in the control and sub‐grouped control. We found no significant difference in genotype and allele frequency distribution between the MCI group and the control group (*P* \> 0.05, Table [3](#psyg12440-tbl-0003){ref-type="table"}), and no significant difference in dominant model and recessive model (*P* \> 0.05, Supplementary Tables [1](#psyg12440-supitem-0001){ref-type="supplementary-material"} and [2](#psyg12440-supitem-0002){ref-type="supplementary-material"}). Further subgroup tests by gender, apolipoprotein E (*APOE*) ε4 and APOE protein phenotypes showed no significant association of the five SNPs with MCI (*P* \> 0.05, Tables [4](#psyg12440-tbl-0004){ref-type="table"} and [5](#psyg12440-tbl-0005){ref-type="table"}).

###### 

Distribution frequencies of genotypes and alleles of subgroup analysis based on apolipoprotein E (APOE) ε4 allele in mild cognitive impairment (MCI) cases and controls

  Single nucleotide polymorphisms    MCI; Control (MM/Mm/mm)  *P* Genotype    MCI; Control (M/m)  *P* Allele   OR (95%CI)
  --------------------------------- ------------------------- -------------- -------------------- ------------ ----------------------
  *APOE* ε4+                                                                                                   
  *BIN1* rs744373 (T \> C)                4/3/0; 19/9/3       0.824              11/3; 47/15      1.000        1.170 (0.288--4.758)
  *NGF* rs6330 (C \> T)                  1/5/1; 12/13/6       0.424               7/7; 37/25      0.508        0.676 (0.211--2.164)
  *OGG1* rs1052133 (C \> G)               4/2/1; 7/20/4       0.179              10/4; 34/28      0.256        2.059 (0.582--7.279)
  *PSEN2* rs8383 (C \> T)                4/3/0; 18/12/1       1.000              11/3; 48/14      1.000        1.069 (0.261--4.374)
  *SORL1* rs1133174 (A \> G)             2/4/1; 13/15/3       0.721               8/6; 41/21      0.549        0.683 (0.209--2.227)
  *APOE* ε4‐                                                                                                   
  *BIN1* rs744373 (T \> C)              15/17/1; 50/36/5      0.537             47/19; 136/46     0.578        0.837 (0.446--1.569)
  *NGF* rs6330 (C \> T)                 15/14/4; 30/41/20     0.318             44/22; 101/81     0.115        1.604 (0.890--2.892)
  *OGG1* rs1052133 (C \> G)             8/16/9; 30/42/19      0.586             32/34; 102/80     0.291        0.738 (0.420--1.298)
  *PSEN2* rs8383 (C \> T)               17/15/1; 47/40/4      1.000             49/17; 134/48     0.922        1.032 (0.543--1.963)
  *SORL1* rs1133174 (A \> G)            12/17/4; 36/46/9      0.837             39/25; 118/64     0.577        0.846 (0.470--1.522)

###### 

Distribution frequencies of genotypes and alleles of subgroup analysis based on apolipoprotein E (APOE) gene protein phenotype in mild cognitive impairment (MCI) cases and controls

  Single nucleotide polymorphisms    MCI; Control (MM/Mm/mm)  *p* Genotype    MCI; Control (M/m)  *p* Allele   OR (95%CI)
  --------------------------------- ------------------------- -------------- -------------------- ------------ -----------------------
  ApoE E2                                                                                                      
  *BIN1* rs744373 (T \> C)                3/2/0; 12/4/1       0.689               8/2; 28/6       1.000        0.857 (0.144--5.097)
  *NGF* rs6330 (C \> T)                   4/1/0; 8/9/0        0.470               9/1; 25/9       0.411        3.240 (0.358--29.299)
  *OGG1* rs1052133 (C \> G)               1/1/3; 4/11/2       0.060               3/7; 19/15      0.150        0.338 (0.075--1.535)
  *PSEN2* rs8383 (C \> T)                 1/4/0; 6/6/5        0.240               6/4; 18/16      0.734        1.333 (0.318--5.590)
  *SORL1* rs1133174 (A \> G)              1/4/0; 9/8/0        0.323               6/4; 26/8       0.422        0.462 (0.104--2.054)
  ApoE E3                                                                                                      
  *BIN1* rs744373 (T \> C)              13/17/1; 43/33/5      0.472             43/19; 119/43     0.539        0.818 (0.430--1.555)
  *NGF* rs6330 (C \> T)                 14/16/1; 41/36/4      0.872             44/18; 118/44     0.779        0.911 (0.477--1.743)
  *OGG1* rs1052133 (C \> G)             8/16/7; 28/35/18      0.643              32/30; 91/71     0.539        0.832 (0.463--1.497)
  *PSEN2* rs8383 (C \> T)               15/11/5; 27/37/17     0.704              41/21; 91/71     0.175        1.523 (0.827--2.805)
  *SORL1* rs1133174 (A \> G)            13/14/4; 33/39/9      0.945             40/22; 105/57     0.967        0.987 (0.535--1.820)
  ApoE E4                                                                                                      
  *BIN1* rs744373 (T \> C)               4/3/0; 15/10/2       1.000              11/3; 40/14      1.000        1.283 (0.312--5.279)
  *NGF* rs6330 (C \> T)                  4/3/0; 16/10/1       1.000              11/3; 42/12      1.000        1.048 (0.251--4.372)
  *OGG1* rs1052133 (C \> G)               4/2/1; 8/16/3       0.274              10/4; 32/22      0.404        1.719 (0.478--6.184)
  *PSEN2* rs8383 (C \> T)                1/4/2; 10/13/4       0.549               6/8; 33/21      0.218        0.477 (0.145--1.571)
  *SORL1* rs1133174 (A \> G)              2/4/1; 8/16/3       1.000               8/6; 32/22      0.886        0.917 (0.279--3.012)

In addition, this study compared the differences in methylation levels of the *DLST* and *OGG1* promoter regions in the MCI group and the control group (Fig. [2](#psyg12440-fig-0002){ref-type="fig"}). The results showed that the methylation levels of *OGG1* and *DLST* genes were not significantly different between the two groups (*P* \> 0.05).

![Association of 8‐oxoguanine DNA glycosylase 1 (*OGG1*) and dihydrolipoamide S‐succinyltransferase (*DLST*) methylation levels with mild cognitive impairment (MCI) in the total and subgroup samples stratified by gender, age, and apolipoprotein E (*APOE*) ε4 (A‐F).](PSYG-19-574-g002){#psyg12440-fig-0002}

*DLST* methylation in female controls was significantly lower than that in male controls (Fig. [2](#psyg12440-fig-0002){ref-type="fig"}, *P* = 0.003). In the *APOE* ε4 subgroup, *DLST* methylation was significantly lower in MCI (Fig. [2](#psyg12440-fig-0002){ref-type="fig"}, *P* = 0.042). in the non‐*APOE* ε4 subgroup, *DLST* methylation in the male controls was significantly lower than that in the female controls (Fig. [2](#psyg12440-fig-0002){ref-type="fig"}, *P* = 0.04). In the non‐*APOE* ε4 carrier younger than 75, *OGG1* methylation was significantly increased in MCI (Fig. [2](#psyg12440-fig-0002){ref-type="fig"}, *P* = 0.049).

We also analyzed the correlation of *DLST* and *OGG1* gene methylation levels with clinical phenotypes. Our results showed there was no significant positive correlation between the methylation levels of *OGG1* and *DLST* genes and age (*P* \> 0.05, data not shown). In the MCI group, *DLST* methylation levels were inversely correlated with LDL (Table [6](#psyg12440-tbl-0006){ref-type="table"}, *r* = −0.311, *P* = 0.048). Further analysis by sex showed there was a positive correlation of FBG and LDL with *OGG1* methylation levels in the female controls (Table [6](#psyg12440-tbl-0006){ref-type="table"}, FBG: *r* = 0.294, *P* = 0.024; HDL: *r* = 0.278, *P* = 0.033). There was a significant inverse correlation between LDL and *DLST* methylation levels in the male MCI group (Table [6](#psyg12440-tbl-0006){ref-type="table"}, [*r*]{.ul} = −0.455, *P* = 0.033). HDL was positively correlated with *DLST* methylation levels in the female control group (Table [6](#psyg12440-tbl-0006){ref-type="table"}, *r* = 0.492, *P* = 0.000).

###### 

Correlation tests between genes (OGG1 and DLST) methylation level and important parameters

           *OGG1*   *DLST*                                                      
  -------- -------- -------- -------- ----------- -------- ----------- -------- -------
  Total                                                                         
  FBG      0.25     0.11     0.111    0.231       −0.061   0.704       0.167    0.074
  TG       −0.203   0.196    −0.052   0.573       0.252    0.112       0.134    0.151
  TC       0.011    0.943    −0.04    0.668       −0.208   0.192       −0.049   0.603
  HDL      0.038    0.81     0.096    0.3         −0.229   0.149       −0.052   0.579
  LDL      0.009    0.956    0.022    0.815       −0.311   **0.048**   0.006    0.953
  Female                                                                        
  FBG      0.233    0.323    0.294    **0.024**   0.139    0.571       0.067    0.619
  TG       −0.338   0.145    −0.038   0.776       0.33     0.167       −0.07    0.601
  TC       0.145    0.543    −0.034   0.8         −0.123   0.616       0.006    0.963
  HDL      0.386    0.093    0.278    **0.033**   −0.404   0.086       0.492    **0**
  LDL      0.072    0.764    0.037    0.78        −0.209   0.391       0.088    0.51
  Male                                                                          
  FBG      0.302    0.172    0.015    0.912       −0.36    0.1         0.105    0.431
  TG       −0.039   0.865    −0.086   0.518       −0.065   0.774       0.137    0.306
  TC       −0.02    0.931    0.067    0.616       −0.364   0.096       −0.065   0.628
  HDL      −0.149   0.507    0.074    0.578       −0.005   0.982       −0.044   0.743
  LDL      −0.014   0.951    0.066    0.622       −0.455   **0.033**   −0.006   0.963

TC, total cholesterol; TG, triglycerides; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; FBG, fasting plasma glucose; *OGG1*, 8‐oxoguanine DNA glycosylase 1; *DLST*, dihydrolipoamide S‐succinyltransferase; Bold, statistically significant

Based on the above results, we further analyzed the interaction of SNPs of five genes. Our results showed that the best model was *OGG1* methylation -- *BIN1* rs744373 -- *OGG1* rs1052133 -- *PSEN2* rs8383 -- *APOE* rs7412 rs429358 (Table [7](#psyg12440-tbl-0007){ref-type="table"}, *P* = 0.001), indicating that the interaction of *OGG1* promoter methylation with several other factors increased the risk of MCI.

###### 

Generalized multi‐factor dimensionality reduction models of high‐order interaction on mild cognitive impairment risk

  Model                                                                                                                                           Training balance accuracy   Testing balance accuracy   Sign test (*P*)   Cross‐validation consistency
  ----------------------------------------------------------------------------------------------------------------------------------------------- --------------------------- -------------------------- ----------------- ------------------------------
  *OGG1* rs1052133 ‐ *APOE* rs7412 rs429358                                                                                                       0.637                       0.4774                     5 (0.6230)        7/10
  *BIN1* rs744373 ‐ *PSEN2* rs8383 ‐ *APOE* rs7412 rs429358                                                                                       0.7084                      0.6363                     8 (0.0547)        10/10
  *BIN1* rs744373 ‐ *OGG1* rs1052133 ‐ *PSEN2* rs8383 ‐ *APOE* rs7412 rs429358                                                                    0.7976                      0.5462                     7 (0.1719)        10/10
  *BIN1* rs744373 ‐ ***NGF* rs6330** ‐ *OGG1* rs1052133 ‐ *PSEN2* rs8383 ‐ *APOE* rs7412 rs429358                                                 0.8741                      0.6461                     **9 (0.0107)**    9/10
  ***DLST* methylation** ‐ *BIN1* rs744373 ‐ *OGG1* rs1052133 ‐ *PSEN2* rs8383 ‐ *APOE* rs7412 rs429358                                           0.8621                      0.5962                     **9 (0.0107)**    10/10
  ***OGG1* methylation** ‐ *BIN1* rs744373 ‐ *OGG1* rs1052133 ‐ *PSEN2* rs8383 ‐ *APOE* rs7412 rs429358                                           0.8767                      0.6395                     **10 (0.0010)**   8/10
  ***DLST* methylation ‐ *OGG1* methylation** ‐ *BIN1* rs744373 ‐ *OGG1* rs1052133 ‐ *PSEN2* rs8383 ‐ *APOE* rs7412 rs429358                      0.9271                      0.595                      8 (0.0547)        10/10
  ***DLST* methylation ‐ *OGG1* methylation** ‐ *BIN1* rs744373 ‐ ***NGF* rs6330** ‐ *OGG1* rs1052133 ‐ *PSEN2* rs8383 ‐ *APOE* rs7412 rs429358   0.9538                      0.5425                     5 (0.6230)        10/10

Bold, statistically significant

DISCUSSION {#psyg12440-sec-0011}
==========

The neuropathological changes in MCI partially overlap with those in AD. For example, neurofibrillary tangles (NFT) and neuritic plaques in the neocortex of the temporal lobe of AD patients can also be seen in MCI patients.[28](#psyg12440-bib-0028){ref-type="ref"} Oxidative DNA damage was also found to be significantly increased in brain tissue and peripheral blood lymphocytes of MCI patients,[29](#psyg12440-bib-0029){ref-type="ref"}, [30](#psyg12440-bib-0030){ref-type="ref"}, [31](#psyg12440-bib-0031){ref-type="ref"} which is consistent with DNA damage caused by oxidative stress (reactive oxygen species (ROS)) in the AD brains.[32](#psyg12440-bib-0032){ref-type="ref"} Therefore, we studied the methylation levels of *DLST* and *OGG1*, which are closely related to ROS.

DLST is one of the three protein subunits of α‐ketoglutarate dehydrogenase complex (KGDHC), and it is the major subunit that affects KGDHC activity.[33](#psyg12440-bib-0033){ref-type="ref"} KGDHC is a rate‐limiting enzyme that mediates the oxidative decarboxylation of α‐ketoglutarate in the tricarboxylic acid (TCA) cycle. Its decreased activity leads to a decrease in glucose metabolism in the brain, which in turn affects cognitive function.[34](#psyg12440-bib-0034){ref-type="ref"} Since abnormal glucose metabolism in the brain is a common feature of dementia and can occur several decades before the clinical symptoms of AD,[35](#psyg12440-bib-0035){ref-type="ref"}, [36](#psyg12440-bib-0036){ref-type="ref"}, [37](#psyg12440-bib-0037){ref-type="ref"} the *DLST* gene is one of the important candidate genes affecting cognitive function. In the present study, we found that the hypomethylation level of the *DLST* promoter interacted with *APOE* ε4 and was associated with the risk of MCI. We also observed that LDL might affect *DLST* promoter methylation and promote the pathogenesis of MCI in males.

OGG1 degrades 8‐oxoG to reduce its damage to DNA bases.[17](#psyg12440-bib-0017){ref-type="ref"} In MCI brains, the 8‐oxoG content was significantly increased, and the activity of OGG1 was significantly decreased.[18](#psyg12440-bib-0018){ref-type="ref"} It has been found that *OGG1* gene polymorphism mutations can alter OGG1 catalytic activity and cause DNA damage, eventually leading to cognitive impairment.[17](#psyg12440-bib-0017){ref-type="ref"} *OGG1* hypermethylation has been found to be significantly associated with aging in mice.[38](#psyg12440-bib-0038){ref-type="ref"} Our study found that the hypermethylation level of the *OGG1* promoter may increase the risk of MCI in the non‐*APOE* ε4 carriers under 75 years of age. Our findings provided a molecular basis for further study of the role of DNA damage in the pathogenesis of MCI.

However, our study did not find that *BIN1* rs744373, *SORL* rs1133174, *PSEN2* rs8383, *NGF* rs6330, *OGG1* rs1052133 polymorphisms were associated with MCI in Chinese Uygur. This might also be due to a moderate sample size in the current study. Therefore, whether the above gene loci are related to MCI and whether there are ethnic differences need to be studied with larger sample sizes.

To further investigate whether DNA methylation interacts with SNPs, we interacted *DLST* and *OGG1* methylation with the five polymorphisms. Our results indicated that the best model was *OGG1* methylation -- *BIN1* rs744373 -- *OGG1* rs1052133 -- *PSEN2* rs8383 -- *APOE* rs7412 rs429358, indicating that the interaction of *OGG1* promoter methylation with several other factors might increase the risk of MCI.

The results of genetic association in this study differ from other research conclusions. Analysis of lifestyle, genetic background, cultural differences, and geographical differences may be the main reasons. Second, the sample size is limited. A larger sample size is needed later to verify our results. Third, older subjects usually have more underlying diseases. Although we have attempted to control confounding factors, unknown influencing factors might still exist. It is necessary to further expand the sample size and verify our findings in other ethnic groups.

This study found for the first time that *DLST* promoter methylation interacts with *APOE* ε4, which affects the pathogenesis of MCI. In addition, *OGG1* promoter methylation interacts with several other factors to increase the risk of MCI.
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###### 

**Supplementary Table 1** Distribution frequencies of dominant model and recessive model in mild cognitive impairment (MCI) cases and controls.

###### 

Click here for additional data file.

###### 

**Supplementary Table 2** Distribution frequencies of dominant model and recessive model of subgroups analyzed based on *APOE* ε4 allele in mild cognitive impairment (MCI) cases and controls.

###### 

Click here for additional data file.

We are grateful to staff who joined in the epidemiological survey in 2015 in Hotan Region, Xinjiang province, China. This research was supported by grants from the National Natural Science Foundation of China (No. 81360064) and the High Technology Research and Development Projects of Xinjiang Province (No. 201517104), and K. C. Wong Magna Fund in Ningbo University.

[^1]: Ting Zou and Wei Chen were co‐first authors of this work.
